Cy­to­ki­net­ic­s' PhI­II car­diomy­opa­thy win sets up show­down with Bris­tol My­ers and sparks M&A spec­u­la­tion

Cy­to­ki­net­ics’ ex­per­i­men­tal med­i­cine for a ge­net­ic heart con­di­tion known as hy­per­trophic car­diomy­opa­thy helped pa­tients do sig­nif­i­cant­ly bet­ter on an ex­er­cise test that’s used to mea­sure heart func­tion, the biotech com­pa­ny an­nounced Wednes­day, send­ing the stock surg­ing and set­ting off spec­u­la­tion about whether it is the sec­tor’s next big deal tar­get.

The late-stage study re­sults put the drug known as afi­camten one step clos­er to com­pet­ing with Camzyos — a sim­i­lar med­i­cine from Bris­tol My­ers Squibb that’s al­ready on the mar­ket for the dis­ease, which leads the heart mus­cle to be­come thick and stiff, ob­struct­ing blood flow. Bris­tol My­ers has pre­vi­ous­ly said that it ex­pects Camzyos to have peak sales of more than $4 bil­lion a year af­ter be­ing ap­proved in 2022.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER